MAPT and early-onset autosomal dominant Alzheimer disease: Alzheimer's disease core biomarkers of tau pathology and neurodegeneration, while changing downstream to Aβ pathology and closer to symptom onset, could be applicable to monitor disease progression and disease activity, which is likely required in upcoming clinical trials.